Cisplatin sensitivity is enhanced by co-treatment with mTOR inhibitors in various other cancers, including ovarian cancer [18, 19], lung cancer [20], and osteosarcoma [21, 24], as well as cervical cancer. Here, MTOR is linked to lung carcinoma.